Identifying safety signals
Signal work aims to identify and describe suspected harm to patients caused by the medicines they use. The evidence comes primarily in the form of spontaneous reports from health professionals across the world, from pharmaceutical companies, and some from patients. Signal work is a core UMC activity.
With the unique resource of VigiBase and by performing signal detection in parallel with method development, UMC is well-positioned to discover new and important signals.
Signals of interest are further evaluated to identify the need for additional data collection, risk mitigation or minimisation activities, or regulatory action.
UMC regularly communicates its signals to national pharmacovigilance centres around the world, or publicly in the WHO Pharmaceuticals Newsletter or a scientific journal.